Evidence map›Paper›PMID 29881678›Full record

ArticleActa pharmaceutica Sinica. B2018

Qiaomei Jin, Xin Shan, Qi Luo, Dongjian Zhang, Yuanyu Zhao, Nan Yao, Fei Peng, Dejian Huang, Zhiqi Yin, Wei Liu and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Editorial for Molecular Imaging and Theranostics.Acta pharmaceutica Sinica. B · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Qiaomei JinAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China.
Xin ShanDepartment of Natural Medicinal Chemistry & Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, China.
Qi LuoAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China.
Dongjian ZhangAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China.
Yuanyu ZhaoDepartment of Natural Medicinal Chemistry & Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, China.
Nan YaoAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China.
Fei PengAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China.
Dejian HuangAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China.
Zhiqi YinDepartment of Natural Medicinal Chemistry & Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, China.
Wei LiuDepartment of Nuclear Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Jian ZhangAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China.
Nanjing University of Chinese Medicine · CNChina Pharmaceutical University · CNJiangsu Provincial Academy of Traditional Chinese Medicine · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Necrosis is a form of cell death, which is related to various serious diseases such as cardiovascular disease, cancer, and neurodegeneration. Necrosis-avid agents (NAAs) selectively accumulated in the necrotic tissues can be used for imaging and/or therapy of related diseases. The aim of this study was to preliminarily investigate necrosis avidity of

Indexed as

131I-EB, 131I-evans blue131I-Evans blueCE-T1WI, contrast-enhanced T1WICT-DNA, calf-thymus DNADMSO, dimethylsulfoxideDNA bindingDWI, diffusion-weighted imagingEB, evans blueH&E, haematoxylin-eosinHyp, hypericin% ID/g, percentage of the injected dose per gram of tissueMPS, mononuclear phagocyte systemMRI, magnetic resonance imagingNAAs, necrosis-avid agentsNecrosis avidityNecrosis imagingPI, propidium iodideRadioactivityRCP, radiochemical purityRFA, radiofrequency ablationRPLI, reperfused liver infarctionSD rats, Sprague–Dawley ratsT1WI, T1-weighted imagingT2WI, T2-weighted imagingTLC, thin layer chromatography

Identifiers

PMID29881678
PMCPMC5989829
OpenAlexW2754085538

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.